The Chiron Corporation has announced that it has decided to discontinue further development of tezacitabine, a next-generation nucleoside analog.
The company has based its decision on an analysis of the data from a Phase II trial in patients with gastroesophageal cancer. The compound did not demonstrate sufficient antitumor activity in the trial.
"Data from the Phase II trial failed to meet Chiron's threshold for moving the program forward," said Dr Stephen Dilly, senior vice president of development, Chiron BioPharmaceuticals.
"We are now evaluating our options for the tezacitabine program".
| The compound did not demonstrate sufficient antitumor activity in the trial.|
"We remain focused on developing new treatments for cancer, including our programs for Proleukin(R) in combination with rituximab and for CHIR258, our growth factor kinase inhibitor."
Chiron acquired tezacitabine in January 2002 with the purchase of Matrix Pharmaceutical.
The side effect profile for tezacitabine is consistent with that of other nucleoside analogs, with fevers and clinically manageable reductions in white blood cell counts being the most commonly reported side effects.